$44.26
1.01% yesterday
Nasdaq, Dec 05, 10:00 pm CET
ISIN
US55910K1088
Symbol
DNTH

Magenta Therapeutics Inc Stock price

$44.26
+10.53 31.22% 1M
+25.69 138.34% 6M
+22.46 103.03% YTD
+20.60 87.07% 1Y
+24.42 123.08% 3Y
-74.78 62.82% 5Y
-188.06 80.95% 10Y
-188.06 80.95% 20Y
Nasdaq, Closing price Fri, Dec 05 2025
-0.45 1.01%
ISIN
US55910K1088
Symbol
DNTH
Industry

Key metrics

Basic
Market capitalization
$1.9b
Enterprise Value
$1.5b
Net debt
positive
Cash
$402.6m
Shares outstanding
42.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
622.4 | 825.9
EV/Sales
491.7 | 652.5
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
94.2%
Return on Equity
-24.1%
ROCE
-25.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1m | $2.3m
EBITDA
$-140.2m | -
EBIT
$-140.3m | $-144.3m
Net Income
$-126.4m | $-147.3m
Free Cash Flow
$-109.6m
Growth (TTM | estimate)
Revenue
-42.6% | -62.8%
EBITDA
-69.8% | -
EBIT
-69.2% | -41.7%
Net Income
-88.3% | -73.3%
Free Cash Flow
-74.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,553.2% | -
EBIT
-4,558.4%
Net
-4,104.8% | -6,346.1%
Free Cash Flow
-3,561.6%
More
EPS
$-3.3
FCF per Share
$-2.6
Short interest
11.0%
Employees
78
Rev per Employee
$80.0k
Show more

Is Magenta Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Magenta Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Magenta Therapeutics Inc forecast:

20x Buy
95%
1x Hold
5%

Analyst Opinions

21 Analysts have issued a Magenta Therapeutics Inc forecast:

Buy
95%
Hold
5%

Financial data from Magenta Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3.08 3.08
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
37% 37%
1,015%
- Research and Development Expense 112 112
71% 71%
3,640%
-140 -140
70% 70%
-4,550%
- Depreciation and Amortization 0.16 0.16
54% 54%
5%
EBIT (Operating Income) EBIT -140 -140
69% 69%
-4,555%
Net Profit -126 -126
88% 88%
-4,102%

In millions USD.

Don't miss a Thing! We will send you all news about Magenta Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Magenta Therapeutics Inc Stock News

Neutral
GlobeNewsWire
12 days ago
NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida.
Neutral
GlobeNewsWire
about one month ago
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGic trial in gMG New claseprubart data from the MaGic open-label extension supporting potential for 300mg/2mL Q4W dosing and new in vitro data highlighting potent...
Neutral
GlobeNewsWire
about one month ago
NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company's participation in four upcoming investor conferences.
More Magenta Therapeutics Inc News

Company Profile

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marino Garcia
Employees 78
Founded 2015
Website dianthustx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today